Tiziana Life Sciences Ltd - AD - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TLSA Nasdaq 8731 https://www.tizianalifesciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tiziana Life Sciences Ltd - AD

Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis - Jun 5th, 2023 2:00 pm
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) - May 25th, 2023 11:00 am
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform - May 23rd, 2023 11:00 am
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17 - May 17th, 2023 11:00 am
TLSA: SPMS Phase II to Proceed - May 2nd, 2023 9:52 am
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference - Apr 27th, 2023 11:00 am
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update - Apr 26th, 2023 6:47 pm
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule - Apr 24th, 2023 11:00 am
Tiziana Life Sciences plans to file Investigational New Drug Application for Alzheimer's treatment - Apr 21st, 2023 2:47 pm
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023 - Apr 20th, 2023 11:00 am
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis - Apr 19th, 2023 2:30 pm
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes - Apr 18th, 2023 11:00 am
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences’ (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise - Apr 17th, 2023 1:00 pm
Tiziana Life Sciences pursuing development of intranasal foralumab for Long COVID treatment - Apr 17th, 2023 9:53 am
EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients - Apr 13th, 2023 12:30 pm
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID - Apr 13th, 2023 11:00 am
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai - Apr 10th, 2023 11:00 am
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference - Apr 4th, 2023 2:43 pm
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage - Apr 4th, 2023 11:00 am
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Sweden - Mar 31st, 2023 11:00 am